To study the effects of EZH2 inhibition in combination with immunotherapy in vivo, we induced tumors to grow in the lungs in Lkb1/Pten mice by adeno-Cre inhalation and after 40–50 weeks, we randomized tumor-bearing mice onto four treatment arms. Here, STK11 is linked to neoplasm.